Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Hamilton

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binderRenee N Brown, Rachel Cameron, David K Chalmers, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human RhinovirusSusanne C Feil, Stephanie Hamilton, Guy Y Krippner, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidaseKeith G Watson, Rachel Cameron, Rob J Fenton, et al.
Journal of Medicinal Chemistry|July 11, 2003
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirusKeith G Watson, Renee N Brown, Rachel Cameron, et al.
JAMA Pediatrics|July 31, 2023
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical TrialBhagwat Gunale, Dhananjay Kapse, Sonali Kar, et al.
Scientific Reports|October 3, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adultsPrasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
Arthritis and Rheumatism|December 21, 2011
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritisCarol A Wallace, Edward H Giannini, Steven J Spalding, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimenSimon J F Macdonald, Keith G Watson, Rachel Cameron, et al.
Journal of Medicinal Chemistry|April 15, 2005
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenzaSimon J F Macdonald, Rachel Cameron, Derek A Demaine, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binderRenee N Brown, Rachel Cameron, David K Chalmers, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human RhinovirusSusanne C Feil, Stephanie Hamilton, Guy Y Krippner, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidaseKeith G Watson, Rachel Cameron, Rob J Fenton, et al.
Journal of Medicinal Chemistry|July 11, 2003
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirusKeith G Watson, Renee N Brown, Rachel Cameron, et al.
JAMA Pediatrics|July 31, 2023
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical TrialBhagwat Gunale, Dhananjay Kapse, Sonali Kar, et al.
Scientific Reports|October 3, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adultsPrasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
Arthritis and Rheumatism|December 21, 2011
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritisCarol A Wallace, Edward H Giannini, Steven J Spalding, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimenSimon J F Macdonald, Keith G Watson, Rachel Cameron, et al.
Journal of Medicinal Chemistry|April 15, 2005
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenzaSimon J F Macdonald, Rachel Cameron, Derek A Demaine, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Pageof 2